What is Charley's Fund?
Established in 2004, Charley's Fund operates as a specialized vehicle dedicated to the translation of scientific research into clinical reality. The organization functions as a bridge between early-stage laboratory discovery and the rigorous demands of clinical trials. With a track record of deploying significant financial resources across more than 50 active treatment programs, the fund maintains a unique market position. It serves not only as a financier but as a strategic partner to the medical community, ensuring that promising research pathways receive the necessary backing to reach patients and their families who are currently underserved by existing therapeutic options.
How much funding has Charley's Fund raised?
Charley's Fund has raised a total of $66K across 1 funding round:
Debt
$66K
Debt (2021): $66K with participation from PPP
Key Investors in Charley's Fund
PPP
Public-Private Partnership
What's next for Charley's Fund?
With the current funding trajectory, Charley's Fund is expected to intensify its focus on late-stage clinical development and regulatory milestones. The strategic deployment of this capital will likely prioritize the scaling of existing treatment programs that have demonstrated the highest potential for efficacy. As the organization moves forward, the focus will remain on optimizing the pipeline of life-saving treatments, fostering collaborative research environments, and maintaining the momentum required to address the complex challenges associated with Duchenne muscular dystrophy. This phase of growth underscores the fund's commitment to long-term sustainability and its role as a catalyst for innovation in the rare disease therapeutic space.
See full Charley's Fund company page
